journal article·2025-11-19

Tumor-Targeted Bacterial Vaccine Induces In Situ Immunogenic Cell Death for Cancer Immunotherapy

Yi Wu, Namei Wu, Youcui Xu, Chen Yang, Han Zhou, Wei Jiang, Jizhou Shen, Hang Liu, Min Li

Nano Letters· Volume 25· Issue 46
Publisher page

Abstract

The immunosuppressive nature and low antigenicity of solid tumors present major obstacles for effective cancer vaccination. Here, we report a live bacteria-based vaccine platform engineered by coating attenuated Salmonella ( SAL ) with a cancer cell membrane (CCM), integrating pathogenic adjuvants and autologous tumor antigens into a single entity. This CCM@ SAL system leverages bacterial immunogenicity to induce immunogenic cell death (ICD) within the tumor microenvironment, promoting in situ release of endogenous antigens and damage-associated molecular patterns. These events synergize to prime antigen-presenting cells and activate tumor-specific T cells. Notably, CCM coating reduces bacterial clearance by phagocytes and enhances tumor accumulation. The combination of ICD induction and tumor-targeted antigen delivery enables a self-amplifying vaccination cycle within the tumor. This in situ vaccination induces durable systemic immunity and suppresses tumor progression in multiple murine models. By integrating tumor targeting, ICD induction, and antigen presentation, CCM@ SAL offers a broadly applicable strategy to improve cancer vaccine efficacy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Cancer Research and Treatments · Nanoplatforms for cancer theranostics · Immunotherapy and Immune Responses

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute of Health and Medicine

Hefei Comprehensive National Science Center

State Key Laboratory of Immune Response and Immunotherapy, Department of Radiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine

University of Science and Technology of China

Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy

Anhui Medical University

Wuxi Institute for Drug Control

School of Chemistry and Chemical Engineering

Anhui University

Funding

University of Science and Technology of China · National Key Research and Development Program of China · Anhui Provincial Department of Science and Technology · China Postdoctoral Science Foundation · National Natural Science Foundation of China · Natural Science Foundation of Anhui Province · Anhui Provincial Key Research and Development Plan · Chinese Academy of Sciences

References (35)

Show source-provided references
1. 10.1016/S0140-6736(25)00553-710.1016/S0140-6736(25)00553-7 ↗
2. 10.1038/s41586-023-06063-y10.1038/s41586-023-06063-y ↗
3. 10.1038/s41577-023-00937-y10.1038/s41577-023-00937-y ↗
4. 10.1021/acs.nanolett.3c0177510.1021/acs.nanolett.3c01775 ↗
5. 10.1038/s41596-022-00713-710.1038/s41596-022-00713-7 ↗
6. 10.1016/j.biomaterials.2017.02.04110.1016/j.biomaterials.2017.02.041 ↗
7. 10.1038/s41571-022-00699-x10.1038/s41571-022-00699-x ↗
8. 10.1038/s41565-020-00781-410.1038/s41565-020-00781-4 ↗
9. 10.1038/s41568-021-00346-010.1038/s41568-021-00346-0 ↗
10. 10.1126/scitranslmed.abc281610.1126/scitranslmed.abc2816 ↗
11. 10.1016/j.nantod.2022.10153710.1016/j.nantod.2022.101537 ↗
12. 10.1146/annurev-pathmechdis-012419-03284710.1146/annurev-pathmechdis-012419-032847 ↗
13. 10.1038/s41586-024-08033-410.1038/s41586-024-08033-4 ↗
14. 10.1038/s41591-019-0498-z10.1038/s41591-019-0498-z ↗
15. 10.1126/scitranslmed.aak953710.1126/scitranslmed.aak9537 ↗
16. 10.1038/s41568-018-0070-z10.1038/s41568-018-0070-z ↗
17. 10.1200/JCO.2002.20.1.14210.1200/JCO.2002.20.1.142 ↗
18. 10.1158/1078-0432.CCR-04-251010.1158/1078-0432.CCR-04-2510 ↗
19. 10.1126/sciadv.aba354610.1126/sciadv.aba3546 ↗
20. 10.1016/j.addr.2022.11436310.1016/j.addr.2022.114363 ↗
21. 10.1016/j.jconrel.2020.07.00910.1016/j.jconrel.2020.07.009 ↗
22. 10.1002/advs.20200357210.1002/advs.202003572 ↗
23. 10.1038/s41467-019-11390-810.1038/s41467-019-11390-8 ↗
24. 10.1038/s41596-024-01019-610.1038/s41596-024-01019-6 ↗
25. 10.1038/s41467-019-13727-910.1038/s41467-019-13727-9 ↗
26. 10.1002/adma.20200240610.1002/adma.202002406 ↗
27. 10.1038/s41573-024-00920-910.1038/s41573-024-00920-9 ↗
28. 10.1038/nri.2016.10710.1038/nri.2016.107 ↗
29. 10.1002/1878-0261.1285110.1002/1878-0261.12851 ↗
30. 10.1038/nrc338010.1038/nrc3380 ↗
31. 10.1146/annurev-immunol-032712-10000810.1146/annurev-immunol-032712-100008 ↗
32. 10.1038/s41467-017-01651-910.1038/s41467-017-01651-9 ↗
33. 10.1021/acs.nanolett.4c0311110.1021/acs.nanolett.4c03111 ↗
34. 10.1016/j.cell.2020.05.01710.1016/j.cell.2020.05.017 ↗
35. 10.1371/journal.pone.004893010.1371/journal.pone.0048930 ↗